A new partnership between the two companies will see development and commercialization of generics with a high technological barrier.
The researchers are currently conducting a National Health and Medical Research Council study using a combination of these nutraceuticals for depression.
The drug is a synthetic androgen available in 100-count bottles of 10-mg tablets.
The drug had an estimated market size of about $4.2 billion for the 12 months ending February 2016, according to IMS Health.
Recently resigned Perrigo chairman and CEO Joseph Papa has joined Valeant Pharmaceuticals as its CEO.
Perrigo's new CEO led the company's U.S. Consumer Healthcare business from 2003 to 2006